Acumen Pharmaceuticals (NASDAQ: ABOS) Presents Data on Enhanced Brain Delivery (EBD) Technology and Early Alzheimer's Disease Insights for Sabirnetug (ACU193) at AAIC 2026 in London (July 12-15): Humanized Monoclonal Antibody Selective for Toxic Soluble Amyloid-Beta Oligomers (AβOs) Relative to Aβ Monomers and Amyloid Plaques, With Phase 2 ALTITUDE-AD Trial Ongoing in Early Symptomatic AD and Topline Results Expected Late 2026 Following Positive Phase 1 INTERCEPT-AD Results
Acumen Pharmaceuticals (NASDAQ: ABOS) will present data on its Enhanced Brain Delivery (EBD) technology and early Alzheimer's disease insights for sabirnetug (ACU193) at AAIC 2026 in London (July 12-15, both in-person and online). Sabirnetug is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble amyloid-beta oligomers (AβOs, a highly toxic and pathogenic form of Aβ) relative to Aβ monomers and amyloid plaques. Soluble AβOs bind to neurons, inhibit synaptic function, and induce neurodegeneration; the mechanism differentiates sabirnetug from plaque-directed anti-amyloid antibodies (lecanemab, donanemab) that clear fibrillar Aβ. Acumen advances sabirnetug in the ongoing Phase 2 ALTITUDE-AD trial in early symptomatic AD, following positive Phase 1 INTERCEPT-AD results. Topline ALTITUDE-AD results are expected in late 2026. The Enhanced Brain Delivery technology component further connects to the day's broader BBB-delivery theme anchored on Denali's opening plenary and the Lonza-Nona deal.